A combination is provided comprising an ellagitannin composition, and an enzymatic composition comprising one or more ellagitannin enzymes, where the one or more ellagitannin enzymes comprise a tannin acyl hydrolase enzyme, a gallate decarboxylase enzyme, or a combination thereof. Methods of making and using combinations disclosed herein are also provided.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components (e.g. microbial components), one or more metabolites (e.g. microbial metabolites), or any combination thereof) for prevention, reduction of risk, treatment, and/or improvement of metabolism (e.g. lipid and cholesterol metabolism) associated diseases, disorders, and conditions are disclosed.
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
5.
METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating insulin-associated diseases, disorders, and conditions are disclosed.
Methods and uses of compositions (e.g. comprising one or more microbial strains, comprising one or more metabolites (e.g. derived from microbial strains or sources other than microbial strains (e.g. synthetically derived)), comprising one or more components, or a combination thereof) for treating eye disorders are disclosed.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
7.
METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or any combination thereof) for prevention, reduction of risk, treatment, and/or improvement of Vagus Nerve associated diseases, disorders, and conditions (e.g. including Vagus nerve and its components (e.g. Vagus nerve system components), including any diseases of organs that are connected to the Vagus Nerve, etc.) are disclosed.
A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/4425 - Dérivés de pyridinium, p. ex. pralidoxime, pyridostigmine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or any combination thereof) for prevention, reduction of risk, treatment, and/or improvement of Vagus Nerve associated diseases, disorders, and conditions (e.g. including Vagus nerve and its components (e.g. Vagus nerve system components), including any diseases of organs that are connected to the Vagus Nerve, etc.) are disclosed.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
9.
Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
10.
METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.
Compositions are provided that extend the lifespan of a subject, and/or reduce or delay the onset of at least one age-associated symptom or condition. In some embodiments, compositions comprise: at least one bacterial strain or extract(s) or component(s) thereof and an excipient. In some embodiments, at least one bacterial strain comprises Gluconobacter spp., Acetobacter spp., Gluconoacaetobacter spp., Acidomonas spp., Ameyamaea spp., Asaia spp., Granulibacter spp., Kozakia spp., Neoasaia spp., Neokomagataea spp., Saccharibacter spp., Swaminathania spp., Tanticharoenia spp., or a combination thereof. Methods of making and using compositions disclosed herein are also provided.
Methods and uses of compositions (e.g. comprising one or more microbial strains, comprising one or more metabolites (e.g. derived from microbial strains or sources other than microbial strains (e.g. synthetically derived)), comprising one or more components, or a combination thereof) for treating eye disorders are disclosed.
A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
16.
MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE
A combination is provided comprising an ellagitannin composition, and an enzymatic composition comprising one or more ellagitannin enzymes, where the one or more ellagitannin enzymes comprise a tannin acyl hydrolase enzyme, a gallate decarboxylase enzyme, or a combination thereof. Methods of making and using combinations disclosed herein are also provided.
Compositions are provided that extend the lifespan of a subject, and/or reduce or delay the onset of at least one age-associated symptom or condition. In some embodiments, compositions comprise: at least one bacterial strain or extract(s) or component(s) thereof and an excipient. In some embodiments, at least one bacterial strain comprises Gluconobacter spp., Acetobacter spp., Gluconoacaetobacter spp., Acidomonas spp., Ameyamaea spp., Asaia spp., Granulibacter spp., Kozakia spp., Neoasaia spp., Neokomagataea spp., Saccharibacter spp., Swaminathania spp., Tanticharoenia spp., or a combination thereof. Methods of making and using compositions disclosed herein are also provided.
C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
20.
MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE
A combination is provided comprising an ellagitannin composition, and an enzymatic composition comprising one or more ellagitannin enzymes, where the one or more ellagitannin enzymes comprise a tannin acyl hydrolase enzyme, a gallate decarboxylase enzyme, or a combination thereof. Methods of making and using combinations disclosed herein are also provided.
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
A combination is provided comprising an ellagitannin composition, and an enzymatic composition comprising one or more ellagitannin enzymes, where the one or more ellagitannin enzymes comprise a tannin acyl hydrolase enzyme, a gallate decarboxylase enzyme, or a combination thereof. Methods of making and using combinations disclosed herein are also provided.
brevets
